HOME >> BIOLOGY >> NEWS
Better techniques needed to predict earthquake hazards, UC study finds

Current methods for estimating the ground-shaking effects of major earthquakes could underestimate their severity and lead to inadequate seismic protection of new and existing buildings, according to a pioneering study of earthquake hazards at three University of California campuses Riverside (UCR), San Diego (UCSD), and Santa Barbara (UCSB).

The study, reported in the April issue of the journal Soil Dynamics and Earthquake Engineering, was conducted in a five-year collaborative research project initiated and directed by Franois Heuze, a geotechnical engineer at Lawrence Livermore National Laboratory (LLNL) near San Francisco. Seven UC campuses participated in the study, known as the Campus Earthquake Program. The researchers found wide discrepancies between their own seismic hazard estimates for the three campuses and those produced by current estimating techniques used for designing new buildings and retrofitting existing buildings.

"The biggest weakness in the current state of the practice for seismic hazard assessment," said Ralph Archuleta, professor of seismology at UCSB, "is that we have very little data for very large earthquakes where the site is close to the causative fault. UCSB, UCR, and UCSD all have major faults that are very close to the campus."

"A single estimate of ground motion for a site is not appropriate," said Heuze. "Even if you have a known fault and restrict your calculations to a known magnitude, this fault could provide that magnitude in many different fashions. Thus the severity of the ground shock where you stand could vary widely."

To try to overcome this problem, the researchers placed several seismic monitoring stations at each campus in boreholes up to 100 meters (330 feet) deep three times the depth of typical geophysical studies and collected data on small earthquakes from local faults as well as regional seismic events. They took and tested soil samples at various depths and simulated hundreds of possi
'"/>

Contact: Charlie Osolin
osolin1@llnl.gov
925-422-8367
DOE/Lawrence Livermore National Laboratory
8-Apr-2004


Page: 1 2 3

Related biology news :

1. Better living through urban ecology
2. Better model of cancer development sheds light on potential angiogenesis target
3. Natural Science and Public Health: Prescription for a Better Environment
4. Better computer modeling provides a new look at large biomolecules
5. UF nutritionist: Better to vow to eat healthy for new year
6. Better "bugs" lead to cheaper ethanol from biomass
7. Diet and cancer prevention: a sampler of story ideas for 5-a-Day for Better Health Week
8. Some Atlantic Coast Beaches Are Shrinking While Floridas Beaches Better Off Than Most
9. New Polyester Products Perform Better And Are Easy To Recycle
10. Better Binding Through Chemistry
11. Urine Tests Will Do Better Than Pelvic Exams To Save Teens From Serious Effects Of Sexually Transmitted Diseases, UCSF Analysis Shows

Post Your Comments:
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: